サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1752982

GLP-1類似体の世界市場

GLP-1 Analogues

出版日
ページ情報
英文 474 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.50円
GLP-1類似体の世界市場
出版日: 2025年06月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 474 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

GLP-1類似体の世界市場は2030年までに1,223億米ドルに到達

2024年に453億米ドルと推定されたGLP-1類似体の世界市場は、2030年には1,223億米ドルに達し、分析期間2024-2030年のCAGRは18.0%で成長すると予測されます。本レポートで分析したセグメントの1つであるオゼンピックGLP-1アナログは、CAGR 19.1%を記録し、分析期間終了時には356億米ドルに達すると予測されます。Trulicity GLP-1 Analogueセグメントの成長率は、分析期間中CAGR 15.3%と推定されます。

米国市場は123億米ドルと推定、中国はCAGR 24.6%で成長予測

米国のGLP-1類似体市場は、2024年に123億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに285億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは24.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ14.2%と16.1%と予測されています。欧州では、ドイツがCAGR約15.0％で成長すると予測されています。

世界の「GLP-1類似体」市場- 主要動向と促進要因のまとめ

なぜGLP-1類似体が糖尿病・肥満治療の展望を変えるのか？

GLP-1（グルカゴン様ペプチド-1）アナログは、グルコース調節と体重減少という二重の役割を果たすことから、2型糖尿病と肥満の治療においてゲームチェンジャーとして登場しました。これらの注射または経口ペプチド薬は、天然ホルモンであるGLP-1を模倣し、インスリン分泌を刺激する一方で、グルカゴンの放出を抑制し、胃排出を遅らせる。糖尿病や代謝性疾患の世界の有病率が急上昇する中、GLP-1類似体は優れた有効性、心血管系への恩恵、旧来の経口抗糖尿病薬に対する嗜好性の高まりから、急速に採用が進んでいます。セマグルチド（オゼンピック、ウェゴビー）やデュラグルチド（トルリシティ）といった画期的な薬剤は、プライマリ・ケアと内分泌の両診療科で強力に採用されています。非糖尿病患者の体重管理における適応外使用の増加傾向は、市場基盤をさらに拡大し、この治療薬クラスにかつてない勢いをもたらしています。

イノベーションはGLP-1療法の進化をどのように牽引しているのか？

GLP-1類似体市場は、ドラッグデリバリー、製剤化、分子設計における急速な技術革新の恩恵を受けています。製薬会社は、半減期の延長、バイオアベイラビリティの改善、週1回あるいは月1回の投与レジメンを備えた次世代類似薬に投資しています。経口GLP-1製剤は、コンプライアンスを向上させ、アクセスを拡大する注射針を使わない選択肢を患者に提供し、人気を集めています。GLP-1/GIPデュアルアゴニストやGLP-1/インスリン製剤の併用などの共同製剤戦略は、血糖プロファイルがコントロールされていない患者や肥満に関連した合併症を有する患者における臨床効果を向上させています。さらに、強固な研究開発パイプラインにより、パッチ、徐放性注射剤、植え込み型デバイスなど、新たなデリバリーメカニズムが研究されています。GLP-1類似体とデジタルヘルスプラットフォーム（スマートペン、グルコース追跡アプリなど）の相乗効果も、治療のアドヒアランスとアウトカムを高めています。

どの地域市場が導入とイノベーションでリードしているか？

北米は現在、肥満率の高さ、強力な保険償還の枠組み、積極的なヘルスケアシステムに牽引され、世界のGLP-1アナログ市場をリードしています。特にFDAによるGLP-1類似体の減量適応の承認後は、米国が処方箋の大きなシェアを占めています。欧州もこれに続き、2型糖尿病の最重要治療薬としてGLP-1療法を支持する国の医療サービスが拡大しています。アジア太平洋では、都市化の進展、生活習慣に関連した健康負担の増加、ヘルスケアインフラの整備が、特に中国、日本、インドでの急速な普及を促しています。一方、ラテンアメリカと中東は新興市場であり、疾患に対する意識の高まりとバイオシミラーGLP-1製剤の入手可能性が普及を後押ししています。また、早期糖尿病患者や糖尿病予備軍に対するGLP-1類似体の処方が、専門医だけでなく一般開業医の間でも受け入れられつつあることも、世界の拡大を後押ししています。

GLP-1類似体市場の主な成長促進要因と阻害要因は？

GLP-1類似体市場の成長は、代謝性疾患による世界の負担の増大、体重および血糖コントロールにおける画期的な臨床成果、強力な医薬品イノベーションによってもたらされます。また、心血管リスクの低減や腎保護におけるこれらの薬剤の役割の拡大も、グルコース・コントロールを超えた価値ある介入として位置づけられています。しかし、治療費の高騰、低所得地域でのアクセス制限、長期的な服薬アドヒアランスを制限する可能性のある消化器系の副作用といった制約に市場は直面しています。さらに、多くのGLP-1製剤は注射剤であるため、経口剤がこのギャップに対処しつつあるとはいえ、特定の層における患者受容の障壁となっています。全体として、臨床的有用性、規制当局のサポート、患者集団の拡大が相まって、GLP-1類似体市場は今後数年間で高成長を遂げることが予想されます。

セグメント

製品タイプ（Ozempic GLP-1アナログ、Trulicity GLP-1アナログ、Mounjaro GLP-1アナログ、Wegovy GLP-1アナログ、Rybelsus GLP-1アナログ、Saxenda GLP-1アナログ、その他GLP-1類似体）、投与経路（皮下投与経路、経口投与経路）、流通チャネル（病院薬局、小売薬局、オンライン流通チャネル）、用途（2型糖尿病用途、肥満症用途、その他用途）

調査対象企業の例（注目の36社）

  • Amgen Inc.
  • AstraZeneca plc
  • Biolingus
  • Boehringer Ingelheim GmbH
  • D&D Pharmatech
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Gmax Biopharm
  • Hanmi Pharmaceutical Co., Ltd.
  • Innovent Biologics, Inc.
  • Jiangsu Hansoh Pharmaceutical Group
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • PegBio Co., Ltd.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sciwind Biosciences Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Viking Therapeutics, Inc.
  • Zealand Pharma A/S

AIインテグレーション

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37005

Global GLP-1 Analogues Market to Reach US$122.3 Billion by 2030

The global market for GLP-1 Analogues estimated at US$45.3 Billion in the year 2024, is expected to reach US$122.3 Billion by 2030, growing at a CAGR of 18.0% over the analysis period 2024-2030. Ozempic GLP-1 Analogue, one of the segments analyzed in the report, is expected to record a 19.1% CAGR and reach US$35.6 Billion by the end of the analysis period. Growth in the Trulicity GLP-1 Analogue segment is estimated at 15.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$12.3 Billion While China is Forecast to Grow at 24.6% CAGR

The GLP-1 Analogues market in the U.S. is estimated at US$12.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$28.5 Billion by the year 2030 trailing a CAGR of 24.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.2% and 16.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.0% CAGR.

Global "GLP-1 Analogues" Market - Key Trends & Drivers Summarized

Why Are GLP-1 Analogues Reshaping the Landscape of Diabetes and Obesity Treatment?

GLP-1 (glucagon-like peptide-1) analogues have emerged as game-changers in the management of type 2 diabetes and obesity, thanks to their dual role in glucose regulation and weight reduction. These injectable or oral peptide drugs mimic the natural hormone GLP-1, stimulating insulin secretion while inhibiting glucagon release and slowing gastric emptying. As the global prevalence of diabetes and metabolic disorders rises sharply, GLP-1 analogues are being rapidly adopted due to their superior efficacy, cardiovascular benefits, and growing preference over older oral antidiabetics. Breakthrough drugs such as semaglutide (Ozempic, Wegovy) and dulaglutide (Trulicity) are seeing strong uptake in both primary care and endocrinology practices. The growing trend of off-label use in weight management among non-diabetic individuals is further expanding the market base, creating unprecedented momentum for this therapeutic class.

How Is Innovation Driving the Evolution of GLP-1 Therapy?

The GLP-1 analogues market is benefiting from rapid innovation in drug delivery, formulation, and molecular design. Pharmaceutical companies are investing in next-generation analogues with extended half-lives, improved bioavailability, and once-weekly or even monthly dosing regimens. Oral GLP-1 formulations are gaining traction, offering patients a needle-free alternative that improves compliance and expands access. Co-formulation strategies-such as GLP-1/GIP dual agonists and GLP-1/insulin combinations-are advancing clinical efficacy in patients with uncontrolled glycemic profiles or obesity-related complications. Additionally, robust R&D pipelines are exploring novel delivery mechanisms including patches, sustained-release injectables, and implantable devices. The synergy between GLP-1 analogues and digital health platforms (e.g., smart pens, glucose tracking apps) is also enhancing treatment adherence and outcomes.

Which Regional Markets Are Leading in Adoption and Innovation?

North America currently leads the global GLP-1 analogue market, driven by high obesity rates, strong reimbursement frameworks, and proactive healthcare systems. The U.S. accounts for a significant share of prescriptions, especially following the approval of GLP-1 analogues for weight loss indications by the FDA. Europe follows closely, where national health services increasingly support GLP-1 therapy as a front-line treatment for type 2 diabetes. In Asia-Pacific, rising urbanization, lifestyle-related health burdens, and healthcare infrastructure upgrades are fostering rapid uptake, particularly in China, Japan, and India. Meanwhile, Latin America and the Middle East are emerging markets, where increased disease awareness and availability of biosimilar GLP-1 products are driving penetration. The global expansion is also supported by growing acceptance among general practitioners, not just specialists, for prescribing GLP-1 analogues in early-stage diabetes and pre-diabetic patients.

What Are the Main Growth Drivers and Constraints in the GLP-1 Analogues Market?

The growth in the GLP-1 analogues market is driven by the escalating global burden of metabolic diseases, breakthrough clinical outcomes in weight and glycemic control, and strong pharmaceutical innovation. The expanding role of these drugs in cardiovascular risk reduction and renal protection also positions them as valuable interventions beyond glucose control. However, the market faces constraints such as high treatment costs, limited access in lower-income regions, and gastrointestinal side effects which may limit long-term adherence. Additionally, the injectable nature of many GLP-1 drugs still poses a barrier for patient acceptance in certain demographics, although oral versions are addressing this gap. Overall, the combined clinical utility, regulatory support, and expanding patient populations indicate a high-growth trajectory for the GLP-1 analogues market in the coming years.

SCOPE OF STUDY:

The report analyzes the GLP-1 Analogues market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue, Other GLP-1 Analogues); Administration Route (Subcutaneous Route, Oral Route); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel); Application (Type 2 Diabetes Mellitus Application, Obesity Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • Amgen Inc.
  • AstraZeneca plc
  • Biolingus
  • Boehringer Ingelheim GmbH
  • D&D Pharmatech
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Gmax Biopharm
  • Hanmi Pharmaceutical Co., Ltd.
  • Innovent Biologics, Inc.
  • Jiangsu Hansoh Pharmaceutical Group
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • PegBio Co., Ltd.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sciwind Biosciences Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Viking Therapeutics, Inc.
  • Zealand Pharma A/S

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • GLP-1 Analogues - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Type 2 Diabetes and Obesity Drives Demand for GLP-1 Analogues
    • Improved Cardiovascular Outcomes Data Strengthens Business Case for GLP-1 as First-Line Therapy
    • Launch of Once-Weekly and Oral Formulations Throws Spotlight on Patient Convenience and Compliance
    • Expanded Indications for Weight Management Create Cross-Sector Market Growth
    • Strong Pipeline Activity and Strategic Partnerships Fuel Innovation and Market Entry
    • Government and Insurance Reimbursement Policies Accelerate Global Access to GLP-1 Drugs
    • High Clinical Efficacy and Low Hypoglycemia Risk Drive Physician Preference for GLP-1 Therapies
    • Integration with Digital Health Platforms and Remote Monitoring Enhances Adherence
    • M&A and Licensing Activity Among Pharma Giants Expand Competitive Landscape and Reach
    • Emerging Research in Neurodegenerative and Cardiometabolic Diseases Broadens Future Applications
    • Direct-to-Consumer Campaigns and Social Awareness Spur Patient-Driven Demand
    • Supply Chain and API Manufacturing Investments Ensure Scalability and Global Market Coverage
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World GLP-1 Analogues Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for GLP-1 Analogues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for GLP-1 Analogues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for GLP-1 Analogues by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Ozempic GLP-1 Analogue by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Ozempic GLP-1 Analogue by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Ozempic GLP-1 Analogue by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Trulicity GLP-1 Analogue by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Trulicity GLP-1 Analogue by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Trulicity GLP-1 Analogue by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Mounjaro GLP-1 Analogue by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Mounjaro GLP-1 Analogue by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Mounjaro GLP-1 Analogue by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Wegovy GLP-1 Analogue by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Wegovy GLP-1 Analogue by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Wegovy GLP-1 Analogue by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Rybelsus GLP-1 Analogue by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Rybelsus GLP-1 Analogue by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Rybelsus GLP-1 Analogue by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Saxenda GLP-1 Analogue by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Saxenda GLP-1 Analogue by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Saxenda GLP-1 Analogue by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other GLP-1 Analogues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other GLP-1 Analogues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other GLP-1 Analogues by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Type 2 Diabetes Mellitus Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Type 2 Diabetes Mellitus Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Obesity Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Obesity Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Obesity Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Subcutaneous Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Subcutaneous Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: World 16-Year Perspective for Subcutaneous Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: World 16-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • GLP-1 Analogues Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 50: USA Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: USA 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: USA 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: USA 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: USA 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 62: Canada Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Canada 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Canada 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Canada 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Canada 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • JAPAN
    • GLP-1 Analogues Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 74: Japan Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Japan 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Japan 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Japan 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 83: Japan Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Japan 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • CHINA
    • GLP-1 Analogues Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 86: China Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: China 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: China 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: China Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: China 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 95: China Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: China Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: China 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • EUROPE
    • GLP-1 Analogues Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 98: Europe Recent Past, Current & Future Analysis for GLP-1 Analogues by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for GLP-1 Analogues by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Europe 16-Year Perspective for GLP-1 Analogues by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Europe 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Europe 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Europe 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 110: Europe Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Europe Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Europe 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • FRANCE
    • GLP-1 Analogues Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 113: France Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: France 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: France 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 119: France Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: France Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: France 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 122: France Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: France Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: France 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • GERMANY
    • GLP-1 Analogues Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 125: Germany Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Germany 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 128: Germany Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Germany 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 131: Germany Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Germany 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 134: Germany Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Germany Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Germany 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 137: Italy Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Italy 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 140: Italy Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Italy 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 143: Italy Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Italy 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 146: Italy Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Italy Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Italy 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • GLP-1 Analogues Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 149: UK Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: UK 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 152: UK Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: UK 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 155: UK Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: UK Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: UK 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 158: UK Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: UK Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: UK 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 161: Spain Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Spain Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Spain 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 164: Spain Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Spain Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Spain 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 167: Spain Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Spain Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Spain 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 170: Spain Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Spain Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Spain 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 173: Russia Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Russia Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Russia 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 176: Russia Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Russia Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Russia 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 179: Russia Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Russia Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Russia 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 182: Russia Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Russia Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Russia 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Europe 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Europe 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Europe Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Europe 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Europe Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Europe 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • GLP-1 Analogues Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Analogues by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for GLP-1 Analogues by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Asia-Pacific 16-Year Perspective for GLP-1 Analogues by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Asia-Pacific 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Asia-Pacific 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Asia-Pacific 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Asia-Pacific Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Asia-Pacific 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • GLP-1 Analogues Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 212: Australia Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Australia Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Australia 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 215: Australia Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Australia Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Australia 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 218: Australia Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Australia Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Australia 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 221: Australia Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Australia Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Australia 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • INDIA
    • GLP-1 Analogues Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 224: India Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: India Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: India 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 227: India Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: India Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: India 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 230: India Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: India Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: India 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 233: India Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: India Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: India 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: South Korea Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: South Korea 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: South Korea Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: South Korea 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 242: South Korea Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: South Korea Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: South Korea 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 245: South Korea Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: South Korea Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: South Korea 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Rest of Asia-Pacific Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Rest of Asia-Pacific 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Rest of Asia-Pacific Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Rest of Asia-Pacific 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • GLP-1 Analogues Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for GLP-1 Analogues by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for GLP-1 Analogues by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Latin America 16-Year Perspective for GLP-1 Analogues by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Latin America 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Latin America 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Latin America Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Latin America 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 272: Latin America Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Latin America Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Latin America 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Argentina Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Argentina 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Argentina Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Argentina 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 281: Argentina Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Argentina Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: Argentina 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 284: Argentina Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Argentina Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: Argentina 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Brazil Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: Brazil 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Brazil Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Brazil 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 293: Brazil Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Brazil Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Brazil 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 296: Brazil Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Brazil Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Brazil 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 299: Mexico Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Mexico Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Mexico 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Mexico Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Mexico 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 305: Mexico Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Mexico Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: Mexico 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 308: Mexico Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Mexico Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 310: Mexico 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Latin America Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 313: Rest of Latin America 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 316: Rest of Latin America 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Rest of Latin America Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 319: Rest of Latin America 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Rest of Latin America Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 322: Rest of Latin America 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • GLP-1 Analogues Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for GLP-1 Analogues by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for GLP-1 Analogues by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 325: Middle East 16-Year Perspective for GLP-1 Analogues by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 328: Middle East 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Middle East Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 331: Middle East 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 332: Middle East Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Middle East Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 334: Middle East 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 335: Middle East Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Middle East Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 337: Middle East 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 338: Iran Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Iran Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 340: Iran 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 341: Iran Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Iran Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 343: Iran 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 344: Iran Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Iran Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 346: Iran 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 347: Iran Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Iran Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 349: Iran 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 350: Israel Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Israel Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 352: Israel 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 353: Israel Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Israel Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 355: Israel 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 356: Israel Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Israel Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 358: Israel 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 359: Israel Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Israel Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 361: Israel 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Saudi Arabia Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 364: Saudi Arabia 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 367: Saudi Arabia 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Saudi Arabia Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 370: Saudi Arabia 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Saudi Arabia Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 373: Saudi Arabia 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 374: UAE Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: UAE Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 376: UAE 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 377: UAE Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: UAE Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 379: UAE 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 380: UAE Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: UAE Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 382: UAE 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 383: UAE Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: UAE Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 385: UAE 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Middle East Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 388: Rest of Middle East 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 391: Rest of Middle East 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Rest of Middle East Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 394: Rest of Middle East 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Rest of Middle East Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 397: Rest of Middle East 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030
  • AFRICA
    • GLP-1 Analogues Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 398: Africa Recent Past, Current & Future Analysis for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Africa Historic Review for GLP-1 Analogues by Product - Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 400: Africa 16-Year Perspective for GLP-1 Analogues by Product - Percentage Breakdown of Value Sales for Ozempic GLP-1 Analogue, Trulicity GLP-1 Analogue, Mounjaro GLP-1 Analogue, Wegovy GLP-1 Analogue, Rybelsus GLP-1 Analogue, Saxenda GLP-1 Analogue and Other GLP-1 Analogues for the Years 2014, 2025 & 2030
    • TABLE 401: Africa Recent Past, Current & Future Analysis for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Africa Historic Review for GLP-1 Analogues by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 403: Africa 16-Year Perspective for GLP-1 Analogues by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 404: Africa Recent Past, Current & Future Analysis for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Africa Historic Review for GLP-1 Analogues by Application - Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 406: Africa 16-Year Perspective for GLP-1 Analogues by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application, Obesity Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 407: Africa Recent Past, Current & Future Analysis for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Africa Historic Review for GLP-1 Analogues by Administration Route - Subcutaneous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 409: Africa 16-Year Perspective for GLP-1 Analogues by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Route and Oral Route for the Years 2014, 2025 & 2030

IV. COMPETITION